Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit

This article was originally published in The Pink Sheet Daily

Executive Summary

Taxotere is the first drug to demonstrate a survival benefit in hormone refractory patients, FDA said. Aventis is investigating docetaxel as first-line therapy.
Advertisement

Related Content

AstraZeneca’s ZD4054 Phase II Shows 24.5-Month Overall Survival In Prostate Cancer
AstraZeneca’s ZD4054 Phase II Shows 24.5-Month Overall Survival In Prostate Cancer
Taxotere Could Get Boost From NICE Prostate Cancer Nod
Taxotere Could Get Boost From NICE Prostate Cancer Nod
Serono/OSI's Novantrone Adds Boxed Warning On Leukemia And Cardiotoxicity
Aventis' Taxotere Gets Breast Cancer Claim With 25.7% Reduction In Relapse Risk
Taxotere Would Be Unaffected By Alimta Approval, Aventis Says
Genta Withdraws NDA For Genasense In Melanoma
Aventis Submits Taxotere sNDA In Early-Stage Breast Cancer; Two More Planned By Early 2005
Aventis Submits Taxotere sNDA In Early-Stage Breast Cancer; Two More Planned By Early 2005

Topics

Advertisement
UsernamePublicRestriction

Register

PS059453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel